ଗ୍ଲୁକାଗନ-ସଦୃଶ ପେପ୍ଟାଇଡ-୧ ରିସେପ୍ଟର ଆଗୋନିଷ୍ଟ

ଗ୍ଲୁକାଗନ-ସଦୃଶ ପେପ୍ଟାଇଡ-୧ ରିସେପ୍ଟର ଆଗୋନିଷ୍ଟ
ଗ୍ଲୁକାଗନ-ସଦୃଶ ପେପ୍ଟାଇଡ-୧ ରିସେପ୍ଟର ଆଗୋନିଷ୍ଟ
Drug class
Class identifiers
Synonyms	GLP-1 receptor agonists, GLP-1 analogs, incretin mimetics
Use	Type 2 diabetes, obesity
Biological target	GLP-1 receptor
Clinical data
Drugs.com	Drug Classes
	In Wikidata

ଗ୍ଲୁକାଗନ-ସଦୃଶ ପେପ୍ଟାଇଡ-୧ ରିସେପ୍ଟର ଆଗୋନିଷ୍ଟ

(ଇଂରାଜୀ ଭାଷାରେ Glucagon-like peptide-1 receptor agonists/ GLP-1-RA ) ଏକ ଔଷଧ ଶ୍ରେଣୀ ଯାହା ମଧୁମେହ ଟାଇପ ୨ ଏବଂ ମେଦ ବ‌ହୁଳତାର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ୨୦୨୨ ସୁଦ୍ଧା ଆଥେରୋସ୍କ୍ଲେରୋସିସ ଥିବା ଟାଇପ୍-୨ ମଧୁମେହ ରୋଗୀଙ୍କର କରୋନାରୀଧମନୀ ରୋଗର ସଙ୍କଟ ଥିବାରୁ ଆମେରିକା ଡାଏବେଟିକ ଆସୋସିଏସନ (ADA) ଏହାକୁ ପ୍ରଥମ ଶ୍ରେଣୀର ଔଷଧ ଭାବରେ ତାଲିକାଭୁକ୍ତ କରିଛି ।^[୪] ଏହା ପାଟିରେ ବା ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଇ, ତରଳ ଝାଡ଼ା ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୫] ଏଥରେ ନିମ୍ନ ରକ୍ତ ଶର୍କରା ହେବାର ଆଶଙ୍କା କମ୍ ଥାଏ; ଯଦିଓ ଏହ ଫଳରେଅଗ୍ନାଶୟ ପ୍ରଦାହ କିମ୍ବା ଗ୍ୟାଷ୍ଟ୍ରୋପାରେସିସ ହୋଇପାରେ ।^[୩] ^[୧] ^[୬] ପଶୁ ମଡେଲଗୁଡ଼ିକରେ ଥାଇରଏଡ୍ ସି-ସେଲ୍ ଟ୍ୟୁମର୍ ବିଷୟରେ ଚିନ୍ତା ବଢ଼ୁଛି ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ଏହାର ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୩] ସେମାନେ ଜିଏଲପି-୧ (GLP-1) ରିସେପ୍ଟରର ସକ୍ରିୟକାରୀ ।^[୧] ସେମାନେ ଇନସୁଲିନ୍ ରିଲିଜ ଅଧିକ କରନ୍ତି ଓ ଉଚ୍ଚ ରକ୍ତ ଶର୍କରା ପ୍ରତିକ୍ରିୟାରେ ଗ୍ଲୁକାଗନ୍ ହ୍ରାସ କରନ୍ତି ଏବଂ ପାକସ୍ଥଳୀ ମନ୍ଥର ଗତିରେ ଖାଲି କରନ୍ତି ।^[୧]

୨୦୦୫ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଏକ୍ସେନାଟାଇଡ ନାମରେ ପ୍ରଥମ ଜିଏଲପି-୧-ଆରଏ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ୨୦୨୨ ସୁଦ୍ଧା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ଅପେକ୍ଷାକୃତ ମହଙ୍ଗା ଯାହା ମାସକୁ ପ୍ରାୟ ୧୦୦୦ ଥିଲା ।^[୪] ଲମ୍ବା କାର୍ଯ୍ୟକାରୀ ଇନସୁଲିନ୍ ସହିତ ପୂର୍ବ ମିଶ୍ରିତ ସଂସ୍କରଣ ଅଛି ।^[୪] ଏହାର ଚାହିଦା ବୃଦ୍ଧି ହେତୁ ୨୦୨୩ ମସିହାରେ ଅଭାବ ଦେଖାଦେଇଥିଲା ।^[୭]^[୮]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ Nauck, MA; Quast, DR; Wefers, J; Meier, JJ (April 2021). "GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art". Molecular metabolism. 46: 101102. doi:10.1016/j.molmet.2020.101102. PMID 33068776.
↑ "List of Incretin mimetics". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 12 May 2023. Retrieved 23 July 2023.
↑ ^୩.୦ ^୩.୧ ^୩.୨ Collins, Logan; Costello, Ryan A. (2023). "Glucagon-like Peptide-1 Receptor Agonists". StatPearls. StatPearls Publishing. Archived from the original on 8 March 2023. Retrieved 23 July 2023.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ American Diabetes Association Professional Practice Committee (January 2022). "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022". Diabetes Care. 45 (Suppl 1): S125–S143. doi:10.2337/dc22-S009. PMID 34964831.
↑ Iqbal, J; Wu, HX; Hu, N; Zhou, YH; Li, L; Xiao, F; Wang, T; Jiang, HL; Xu, SN (June 2022). "Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials". Obesity reviews : an official journal of the International Association for the Study of Obesity. 23 (6): e13435. doi:10.1111/obr.13435. PMID 35194917.
↑ Young, Clipper F.; Moussa, Marianne; Shubrook, Jay H. (1 August 2020). "Diabetic Gastroparesis: A Review". Diabetes Spectrum. 33 (3): 290–297. doi:10.2337/ds19-0062.
↑ Jankovic, Saša (28 June 2023). "Government declares 'national shortage' of GLP-1 receptor agonists for type 2 diabetes until 2024". The Pharmaceutical Journal. Archived from the original on 20 July 2023. Retrieved 23 July 2023.
↑ Cruz, Jace (11 July 2023). "Global Shortage of Diabetes Medicine 'Ozempic' Could Persist for a Longer Time, Experts Claim". Retrieved 23 July 2023.

[Nau2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ Nauck, MA; Quast, DR; Wefers, J; Meier, JJ (April 2021). "GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art". Molecular metabolism. 46: 101102. doi:10.1016/j.molmet.2020.101102. PMID 33068776.

[2] "List of Incretin mimetics". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 12 May 2023. Retrieved 23 July 2023.

[Stat2023-3] ୩.୦ ^୩.୧ ^୩.୨ Collins, Logan; Costello, Ryan A. (2023). "Glucagon-like Peptide-1 Receptor Agonists". StatPearls. StatPearls Publishing. Archived from the original on 8 March 2023. Retrieved 23 July 2023.

[ADA2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ American Diabetes Association Professional Practice Committee (January 2022). "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022". Diabetes Care. 45 (Suppl 1): S125–S143. doi:10.2337/dc22-S009. PMID 34964831.

[Iq2022-5] Iqbal, J; Wu, HX; Hu, N; Zhou, YH; Li, L; Xiao, F; Wang, T; Jiang, HL; Xu, SN (June 2022). "Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials". Obesity reviews : an official journal of the International Association for the Study of Obesity. 23 (6): e13435. doi:10.1111/obr.13435. PMID 35194917.

[6] Young, Clipper F.; Moussa, Marianne; Shubrook, Jay H. (1 August 2020). "Diabetic Gastroparesis: A Review". Diabetes Spectrum. 33 (3): 290–297. doi:10.2337/ds19-0062.

[7] Jankovic, Saša (28 June 2023). "Government declares 'national shortage' of GLP-1 receptor agonists for type 2 diabetes until 2024". The Pharmaceutical Journal. Archived from the original on 20 July 2023. Retrieved 23 July 2023.

[8] Cruz, Jace (11 July 2023). "Global Shortage of Diabetes Medicine 'Ozempic' Could Persist for a Longer Time, Experts Claim". Retrieved 23 July 2023.

[୨]

[୩]

[୧]

[୪]

[୫]

[୬]

[୭]

[୮]